Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Blast Crisis 1

Interventions

daratumumab 3Dexamethasone 3Bortezomib 2sodium thiosulfate 1pomalidomide 1pembrolizumab 1etoposide phosphate 1darlin protein, Dictyostelium 1bosutinib 1Thalidomide 1Restraint, Physical 1Pemetrexed 1Mitoxantrone 1Lenalidomide 1Gemtuzumab 1Etoposide 1Daunorubicin 1Cytarabine 1Crizotinib 1Cisplatin 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Has announcements × bosutinib × Clear all
NCT04258943 2025-09-18

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Active not recruiting
60 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡